Supporting Information

for

Synthesis of acylhydrazino-peptomers, a new class of peptidomimetics, by consecutive Ugi and hydrazino-Ugi reactions

Angélica de Fátima S. Barreto,* Veronica Alves dos Santos and Carlos Kleber Z. Andrade*

Address: Laboratório de Química Metodológica e Orgânica Sintética, Instituto de Química, Universidade de Brasília, CP 4478, 70910-970 Brasília-DF, Brazil.

Email: Carlos Kleber Z. Andrade* - ckleber@unb.br

*Corresponding author

Detailed experimental procedures, NMR and mass spectra of all compounds

General information	S2
General procedure for the preparation of hydrazides	S2
General procedure for the preparation of Boc-protected amido acids	S3
References	S14
Spectra of compounds	S15–S57

Experimental

General information

NMR spectra were recorded on a Bruker Ascend instrument using a 5-mm internal diameter probe operating at 600 MHz for ¹H and at 150 MHz for ¹³C or in a Varian Mercury Plus 300 spectrometer at 300 MHz for ¹H and 75.46 MHz for ¹³C both in the presence of TMS as internal standard. High resolution ESI(+)-MS analyses were carried out on a triple TOF 5600+ (AB Sciex) with internal calibration and direct solution (1 ppm) infusion. Reactions under microwave were performed on a CEM Co. Discover microwave reactor using sealed vessels, dynamic program, and temperature detection by internal fiber optic probe and media stirring. TLC plates were revealed by treatment with a 10% solution of phosphomolybdic acid in ethanol, followed by heating. Melting points were recorded on a Marconi melting point and are uncorrected. Commercially available reagents and solvents were analytical grade or were purified by standard procedures prior to use. Compounds were analyzed by ¹H NMR, ¹³C NMR and high resolution ESI mass spectra giving data consistent with the proposed structures.

General procedure for the preparation of hydrazides [1]

The ester (10.0 mmol) was added in small portions to a solution of hydrazine hydrate (40.0 mmol) in 3.0 mL of ethanol. After refluxing for 3–6.5 h, the residue was concentrated in vacuum and purified by column chromatography.

General procedure for the preparation of *Boc*-protected amino acids [2]

The amino acid (10.0 mmol) was dissolved in dioxane/water (2:1, 30 mL), which was made alkaline with NaOH (1 M, 10 mL) and cooled in an ice-bath, and $(Boc)_2O$ (3.27 g, 15.0 mmol) and NaHCO₃ (0.84 g, 10.0 mmol) were added. The reaction mixture was stirred overnight at room temperature and was then evaporated to half the volume. The residue was diluted with EtOAc (40 mL), cooled in an ice-bath and acidified to pH = 2.5–3.0 with KHSO₄ (1 M). The layers were separated, the aqueous fraction was extracted with EtOAc (2 × 20 mL), and the combined organic extracts were washed with water, dried and evaporated to yield the respective *Boc*-Amino acid, which was used in the next step without further purification.

Cbz-glycine hydrazide (3a) [3]

To a stirred solution of *Cbz*-glycine (**1**, 2.56 mmol, 0.54 g) in DMF (3.0 mL) was added sodium bicarbonate (3.38 mmol, 0,28 g) followed by methyl iodide (9.64 mmol, 0.60 mL). The mixture was stirred under nitrogen atmosphere for 46 h at room temperature. After this time, 30 mL of ethyl acetate was added and the mixture was washed with distilled water (three times). The organic phase was separated, dried with sodium sulfate and concentrated to yield product **2** (2.38 mmol, 0.53 g, 93% yield), which was used without further purification. Compound **3a** was prepared following the general procedure for the preparation of hydrazide (refluxing for 3 h) using product **2** (4.93 mmol, 1.10 g), hydrazine hydrate (17.2 mmol, 0.86 g) and 1.4 mL of ethanol. Purification by column chromatography (CH₂Cl₂ \rightarrow 10% MeOH/CH₂Cl₂) furnished **3a** in 69% yield (0.76 g, 3.42 mmol) as a white solid. R_f (CH₂Cl₂/MeOH 15%) = 0.51. m.p = 112st 114 °C. ¹H NMR (300 MHz, CD₃OD) δ 7.37-7.27 (m, 5H), 5.09 (s, 2H), 3.76 (s, 2H). ¹³C NMR (75.46 MHz, CDCl₃) δ 171.4, 158.9, 138.0, 129.4, 129.0, 128.9, 67.8, 43.6.

Boc-glycine hydrazide (3b)[4]

Compound **5** was prepared following the general procedure for the preparation of *Boc*-amino acids using glycine methyl ester hydrochloride (1.25 g, 10.0 mmol) in quantitative yields as a colorless oil, which was used without further purification. Compound **3b** was then prepared following the general procedure for the preparation of hydrazide (refluxing for 3 h) using ester **5** (9.90 mmol, 1.87 g), hydrazine hydrate (39.6 mmol, 1.98 g) and 3.0 mL of ethanol. Purification by column chromatography (CH₂Cl₂ \rightarrow 10% MeOH/CH₂Cl₂) furnished *Boc*-glycine hydrazide (**3b**) in 78% yield (1.45 g, 7.67 mmol) as a white solid. R_f (CH₂Cl₂/MeOH 15%) = 0.43. m.p = 105-107 °C. ¹H NMR (300 MHz, CD₃OD) δ 3.68 (s, 2H), 1.44 (s, 9H). ¹³C NMR (75.46 MHz, CD₃OD) δ 171.9, 158.6, 80.9, 43.5, 28.8.

Hydrazide 3c

Compound **7** was prepared in 73% yield as a viscous colorless oil following the general procedure for the preparation of *Boc*-Amino acids using amine **6** (1.46 g, 10.0 mmol) and was used without further purification. Compound **3c** was then prepared following the general procedure for the preparation of hydrazide (refluxing for 3 h) using ester **7** (4.35 mmol, 1.07 g), hydrazine hydrate (17.4 mmol, 0.87 g) and 2.3 mL of ethanol. Purification by column chromatography $(CH_2Cl_2 \rightarrow 15\% \text{ MeOH/CH}_2Cl_2)$ furnished hydrazide **3c** in 47% yield (0.51 g,

2.05 mmol) as a white solid. $R_f (CH_2Cl_2/MeOH 15\%) = 0.24$. m.p = 44-46 °C. ¹H NMR (300 MHz, CD₃OD) δ 3.87 (s, 2H), 3.73 (s, 2H), 1.46 (s, 9H). ¹³C NMR (75.46 MHz, CDCl₃) δ 173.3, 170.9, 158.8, 81.0, 44.9, 42.4, 28.8. HRMS (ESI) *m/z*: calcd. for [M+Na]⁺ C₉H₁₈N₄O₄Na: 269.1226; found: 269.1217.

Compound 11a

To a stirred solution of Cbz-glycine hydrazide (3a, 2.13 mmol, 0.476 g) in methanol (4.0 mL) was added isobutyraldehyde (8a, 2.13 mmol, 0.19 mL) and stirring was continued for 0.5 h at room temperature. After the solvent was evaporated and the imine was dissolved in trifluoroethanol (4.5 mL), acetic acid (10b, 2.13 mmol, 0.122 mL) and methyl isocyanoacetate (9, 2.13 mmol, 0.19 mL) were added. After stirring for 18 h at room temperature, the solution was concentrated in vacuum and the residue was purified by column chromatography (CH₂Cl₂ \rightarrow 2% MeOH/CH₂Cl₂) to yield ester **11a** (1.47 mmol, 0.64 g, 69% yield) as a beige solid. $R_f (CH_2Cl_2/MeOH 10\%) = 0.54$. m.p = 103-105 °C. ¹H NMR (600 MHz, CDCl₃, presence of rotamers) δ 9.09-8.89 (2 br s, 1H), 7.35-7.30 (m, 5H), 7.13 (br s, 1H), 5.82 and 5.58 (2 br s, 1H), 5.13 (s, 2H), 4.72 (d, J = 9.5 Hz, 1H), 4.06-3.84 (m, 4H), 3.72 (s, 3H), 2.24-2.12 (m, 1H), 2.07 (s, 3H), 1.02-0.91 (m, 6H).¹³C NMR (150 MHz, CDCl₃, presence of rotamers): δ 174.2; 171.2; 170.3; 168.3; 156.6; 136.0; 128.5; 128.0; 67.3; 64.3; 52.4; 43.3; 40.9; 27.2; 20.9; 19.8; 19.3. HRMS (ESI) *m/z*: calcd. for [M+Na]⁺ C₂₀H₂₈N₄O₇Na: 459.1856; found: 459.1848.

Compound 11b

To a stirred solution of Boc-glycine hydrazide (3b, 0.50 mmol, 0.094 g) in methanol (1.0 mL) was added isobutyraldehyde (8a, 0.50 mmol, 0.45 mL) and stirring was continued for 2 h at room temperature. After the solvent was evaporated and the imine was dissolved in trifluoroethanol (2.0 mL), acetic acid (10b, 0.25 mmol, 0.014 mL) and methyl isocyanoacetate (9, 0.25 mmol, 0.023 mL) were added. After stirring for 43 h at room temperature, the solution was concentrated in vacuum and the residue was purified by column chromatography (CH₂Cl₂ \rightarrow 2% MeOH/CH₂Cl₂) to yield ester **11b** (0.293 mmol, 0.118 g, 59%) as a white solid. R_f (CH₂Cl₂/MeOH 10%) = 0.51. m.p. = 160-162 ^oC. ¹H NMR (300 MHz, CDCl₃, presence of rotamers) δ 8.99 (br s, 1H), 6.83 (br s, 1H), 5.16 (br s, 1H), 4.64 (br s, 1H), 3.97 (s, 2H), 3.82 (s, 2H), 3.73 (s, 3H), 2.27-2.14 (m, 1H), 2.07 (s, 3H), 1.42 (s, 9H), 1.02 (s, 3H), 0.95 (d, J = 6.6 Hz, 3H). ¹³C NMR (150 MHz, DMSO- d_6 , presence of rotamers): δ 172.3, 170.8, 169.9, 169.1, 155.8, 78.3, 63.4, 51.6, 42.4, 40.5, 28.1, 26.9, 20.6, 19.1, 18.7. HRMS (ESI) m/z: calcd. for $[M+Na]^+$ $C_{19}H_{27}N_3O_6Na$: 425.2012; found: 425.2012.

Compound 11c

To a stirred solution of hydrazine **3b** (1.59 mmol, 0.30 g) in trifluoroethanol (2.0 mL) was added ketone **8b** (3.18 mmol, 0.23 mL) and stirring was continued for 2 h at room temperature. Then were added sodium sulfate (0.30 g), propanoic acid (**10c**, 0.79 mmol, 0.059 mL) and methyl isocyanoacetate (**9**, 0.79 mmol, 0.072 mL). After stirring for 40 h at room temperature, the solution was concentrated in vacuum and the residue was purified by column

chromatography (CH₂Cl₂ \rightarrow 4% MeOH/CH₂Cl₂) to yield ester **11c** (0.714 mmol, 0.287 g, 90%) as a viscous light yellow oil. R_f (CH₂Cl₂/MeOH 10%) = 0.47. ¹H NMR (600 MHz, CDCl₃, presence of rotamers) δ 9.65 (br s, 1H), 8.73 (br s, 1H), 5.70 (br s, 1H), 4.11 (dd, *J* = 5.9 and 18.0 Hz, 1H), 3.97-3.96 (m, 2H), 3.92 (dd, *J* = 5.1 and 18.0 Hz, 1H), 3.71 (s, 3H), 2.42-2.36 and 2.25-2.19 (2m, 2H), 1.45 (s, 12H), 1.36 (s, 3H), 0.99 (t, *J* = 7.3 Hz, 3H). ¹³C NMR (150 MHz, CDCl₃, presence of rotamers): δ 175.6, 175.1, 172.6, 170.3, 156.2, 80.4, 64.5, 52.1, 42.9, 41.6, 28.2, 26.2, 24.5, 22.2, 8.3. HRMS (ESI) *m/z*: calcd. for [M+Na]⁺ C₁₇H₃₀N₄O₇Na: 425.2012; found: 425.2013.

Compound 11d

To a stirred solution of hydrazine **3b** (0.50 mmol, 0,094 g) in trifluoroethanol (1.0 mL) was added ketone **8b** (1.0 mmol, 0.073 mL) and stirring was continued for 1 h at room temperature. Then were added sodium sulfate (0.50 g), formic acid (**10a**, 0.25 mmol, 0.009 mL) and methyl isocyanoacetate (**9**, 0.25 mmol, 0.023 mL). After stirring for 24 h at room temperature, the solution was filtrated, concentrated in vacuum and the residue was purified by column chromatography ($CH_2CI_2 \rightarrow 4\%$ MeOH/ CH_2CI_2) to yield ester **11d** (0.25 mmol, 0.084 g, 90%) as a viscous light yellow oil. R_f ($CH_2CI_2/MeOH$ 10%) = 0.48. ¹H NMR (600 MHz, CDCI₃, presence of rotamers) δ 9.50 (br s, 1H), 8.69 and 8.59 (2 br s, 1H), 8.29 and 8.00 (2s, 1H), 5.52 (br s, 1H), 4.03-3.96 (m, 4H), 3.73 (s, 3H), 1.58 (s, 3H), 1.46-1.44 (m, 12H). ¹³C NMR (150 MHz, CDCI₃, presence of rotamers): δ 174.4, 170.4, 164.2, 161.4, 156.1, 80.4, 63.9, 52.1, 42.6, 41.5, 28.2, 25.5, 23.6. HRMS (ESI) *m/z*: calcd. for [M+Na]⁺ C₁₅H₂₆N₄O₇Na: 397.1699; found: 397.1703.

Compound 11e

To a stirred solution of hydrazine **3c** (2.13 mmol, 0,524 g) in methanol (4.0 mL) was added isobutyraldehyde (8a, 2.13 mmol, 0.19 mL) and stirring was continued for 1 h at room temperature. After the solvent was evaporated and the imine was dissolved in TFE (4.0 mL), were added acetic acid (10b, 2.13 mmol, 0.12 mL) and methyl isocyanoacetate (9, 2.13 mmol, 0.19 mL). After stirring for 48 h at room temperature, the solution was concentrated in vacuum and the residue was purified by column chromatography (CH₂Cl₂ \rightarrow 2% MeOH/CH₂Cl₂) to yield the ester **11e** (1.55 mmol, 0.710 g, 73%) as a yellow solid. R_f (CH₂Cl₂/MeOH 10%) = 0.38. m.p = 57-59 °C. ¹H NMR (600 MHz, CDCl₃, presence of rotamers) δ 9.32 and 9.25 (2s, 1H), 7.53 and 7.49 (2s, 1H), 5.63 and 5.53 (2s, 1H), 4.61 (d, J = 9.2 Hz, 1H), 4.00 and 3.87 (2 br s, 6H), 3.75 (s, 3H), 2.25-2.15 (m, 1H), 2.08 (s, 3H), 1.44 (s, 9H), 1.10-0.97 (m, 6H). ¹³C NMR (150 MHz, CDCl₃, presence of rotamers): δ 174.1, 171.0, 170.4, 169.7, 168.3, 156.5, 80.5, 65.2, 52.4, 44.2, 41.9, 41.0, 27.2, 20.9, 19.8, 19.4, 19.2. HRMS (ESI) m/z: calcd. for $[M+Na]^+$ $C_{19}H_{33}N_5O_8Na$: 482.2227; found: 482.2228.

Compound 11f

To a stirred solution of hydrazine **3c** (1.62 mmol, 0,398 g) in methanol (3.0 mL) was added isobutyraldehyde (**8a**, 1.62 mmol, 0.15 mL) and stirring was continued for 1 h at room temperature. After the solvent was evaporated and the imine was dissolved in TFE (3.0 mL), were added propanoic acid (**10c**, 1.62 mmol, 0.12 mL) and methyl isocyanoacetate (**9**, 1.62 mmol, 0.15 mL). After stirring for 51 h at room temperature, the solution was concentrated in vacuum

and the residue was purified by column chromatography (CH₂Cl₂ \rightarrow 4% MeOH/CH₂Cl₂) to yield ester **11f** (1.15 mmol, 0.543 g, 71%) as a light yellow solid. R_f (CH₂Cl₂/MeOH 10%) = 0.46. m.p = 53-55 °C. ¹H NMR (600 MHz, CDCl₃, presence of rotamers) δ 9.27 and 9.20 (2 br s, 1H), 7.58 (br s, 1H), 7.33 (br s, 1H), 5.68 and 5.57 (2 br, 1H), 4.63 (s, 1H), 4.20-3.78 (m, 6H), 3.74 (s, 3H), 2.47-2.31 (m, 2H), 2.27-2.17 and 2.14-2.05 (2m, 1H), 1.44 (s, 9H), 1.14-0.91 (m, 9H). ¹³C NMR (150 MHz, CDCl₃, presence of rotamers): δ 177.1, 171.3, 170.4, 169.6, 168.4, 156.4, 80.5, 65.6, 52.4, 44.2, 41.9, 41.0, 28.3, 27.3, 25.7, 20.0, 19.5, 8.6. HRMS (ESI) *m/z*: calcd. for [M+Na]⁺ C₂₀H₃₅N₅O₈Na: 496.2383; found: 496.2379.

Hydrazide 12a

Compound **12a** was prepared following the general procedure for the preparation of hydrazides (refluxing 5 h) using ester **11b** (0.71 mmol, 0.286 g), hydrazine hydrate (2.84 mmol, 0,14 mL) and 3.3 mL of ethanol. Purification by column chromatography (CH₂Cl₂ \rightarrow 15% MeOH/CH₂Cl₂) furnished hydrazide **12a** in 72% yield (0.51 mmol, 0.205 g) as a white solid. R_f (CH₂Cl₂/MeOH 15%) = 0.29. m.p = 59-61 °C. ¹H NMR (600 MHz, CD₃OD, presence of rotamers) $\overline{0}$ 4.63 (d, *J* = 9.5 Hz, 1H), 3.96-3.68 (m, 4H), 2.24-2.12 (m, 1H), 1.45 (s, 9H), 1.01-0.89 (m, 6H). ¹³C NMR (150 MHz, CD₃OD, presence of rotamers) $\overline{0}$ 175.9, 173.1, 171.7, 170.6, 158.6, 80.9, 64.9, 43.4, 42.9, 28.8, 27.9, 20.9, 20.5, 19.5. HRMS (ESI) *m/z*: calcd. for [M+Na]⁺ C₁₆H₃₀N₆O₆Na: 425.2125; found: 425.2124.

Hydrazide 12b

Compound **12b** was prepared following the general procedure for the preparation of hydrazides (refluxing 5 h) using ester **11f** (0.890 mmol, 0.421 g), hydrazine hydrate (3.56 mmol, 0.17 mL) and 4.0 mL of ethanol. Purification by column chromatography (CH₂Cl₂ \rightarrow 15% MeOH/CH₂Cl₂) furnished hydrazide **12b** in 72% yield (0.64 mmol, 0.304 g) as a white solid. R_f (CH₂Cl₂/MeOH 15%) = 0.31. m.p = 101-103 °C. ¹H NMR (600 MHz, CD₃OD) δ 4.67 (d, *J* = 9.5 Hz, 1H), 4.04-3.66 (m, 6H), 2.46-2.40 (m, 1H), 2.32-2.13 (m, 2H), 1.45 (s, 9H), 1.07 (t, *J* = 7.5 Hz, 3H), 1.02-0.91 (m, 6H). ¹³C NMR (150 MHz, CD₃OD) δ 178.6, 173.4, 172.1, 171.7, 170.5, 158.6, 80.7, 64.8, 44.7, 42.8, 42.2, 28.7, 27.8, 26.7, 20.3, 19.4, 9.4. HRMS (ESI) *m/z*: calcd. for [M+H]⁺ C₁₉H₃₆N₇O₇: 474.2676; found: 474.2670.

Compound 14a

To a stirred solution of hydrazide **12a** (0.472 mmol, 0.190 g) in trifluoroethanol (2.0 mL) was added ketone **8b** (1.89 mmol, 0.14 mL) and stirring was continued for 1 h at room temperature. Then were added propanoic acid (**10c**, 0.472 mmol, 0.035 g) and methyl isocyanoacetate (**9**, 0.472 mmol, 0.043 mL). After stirring for 45 h at room temperature, the solution was concentrated in vacuum and the residue was purified by column chromatography (CH₂Cl₂ \rightarrow 8% MeOH/CH₂Cl₂) to yield compound **14a** (0.281 mmol, 0.173 g, 60% yield) as a yellow solid. R_f (CH₂Cl₂/MeOH 10%) = 0.48. m.p = 118-120 °C. ¹H NMR (600 MHz, CD₃OD) δ 4.64 (d, *J* = 9.5 Hz, 1H), 4.31-3.74 (m, 6H), 3.72 and 3.69 (2s, 3H), 2.43-2.32 (m, 1H), 2.26-2.13 (m, 2H), 2.07-2.02 (m, 3H), 1.46-1.31 (m, 15H), 1.03-0.88 (m, 9H). ¹³C NMR (150 MHz, DMSO-*d*₆) δ 175.3, 173.8, 173.6,

172.1, 170.1, 169.2, 168.7, 155.8, 78.2, 63.5, 61.5, 51.6, 51.4, 48.7, 40.8, 28.0, 25.7, 24.0, 22.4, 20.6, 19.3, 18.8, 8.4. HRMS (ESI) *m/z*: calcd. for [M+Na]⁺ C₂₆H₄₅N₇O₁₀Na: 638.3126; found: 638.3115.

Compound 14b

To a stirred solution of hydrazide **12b** (0.361 mmol, 0.171 g) in trifluoroethanol (2.0 mL) was added ketone 8b (1.44 mmol, 0.11 mL) and stirring was continued for 3 h at room temperature. Then were added propanoic acid (10c, 0.180 mmol, 0.013 mL) and methyl isocyanoacetate (9, 0.180 mmol, 0.016 mL). After stirring for 40 h at room temperature, the solution was concentrated in vacuum and the residue was purified by column chromatography (CH₂Cl₂ \rightarrow 8% MeOH/CH₂Cl₂) to yield compound **14b** (0.161 mmol, 0.076 g, 90% yield) as a yellow solid. R_f (CH₂Cl₂/MeOH 10%) = 0.39. m.p = 107-109 °C. ¹H NMR (600 MHz, CDCl₃) δ 9.81 and 9.74 (2br s, 1H), 9.67 and 9.63 (2br s, 1H), 8.88 and 8.79 (2 br s, 1H), 8.58 and 8.26 (2 br s, 1H), 7.83 and 7.76 (2 br s, 1H), 5.88 and 5.81 (2 br s, 1H), 4.60 and 4.50 (s, 1H), 4.10-3.75 (m, 8H), 3.73 and 3.71 (2s, 3H), 2.49-2.39 (m, 1H), 2.35-2.18 (m, 4H), 1.46-1.34 (m, 15H), 1.06-0.92 (m, 12H). ¹³C NMR (150 MHz, CDCl₃) δ 175.4; 175.2; 174.8; 171.4; 171.2; 170.8; 170.5; 170.1; 169.3; 80.9; 71.8; 64.5; 52.1; 49.4; 44.6; 42.2; 41.7; 41.2; 29.7; 28.3; 24.9; 22.0; 19.2; 14.1; 8.7. HRMS (ESI) m/z: calcd. for [M+Na]⁺ C₂₉H₅₀N₈O₁₁Na: 709.3497; found: 709.3495.

Compound 15a

A sealed 10 mL glass tube containing a solution of ester **11a** (0.47 mmol, 0.205 g) in THF/H₂O (2:1, 7.5 mL) and LiOH (1.18 mmol, 0.028 g) at room S11

temperature was introduced in the cavity of a microwave reactor (CEM Co., Discover) and irradiated at 60 °C for 5 min under magnetic stirring. The reaction mixture was then acidified with a 2 M solution of NaHSO₄ to pH 2 and extracted twice with ethyl acetate (2 × 30 mL). The organic phase was dried with sodium sulfate, filtered and concentrated to yield acid **13a** (0.44 mmol, 0.185 g, 94%), which was used without further purification. A mixture of acid 13a (0.44 mmol, 0.185 g), methanol (1.5 mL), anhydrous sodium sulfate (0.20 g), paraformaldehyde (0.88 mmol, 0.0264 g), benzylamine (0.88 mmol, 0.094 g) and methyl isocyanoacetate (0.44 mmol, 0.040 mL) was introduced in the cavity of a microwave reactor (CEM Co., Discover) and irradiated at 80 °C for 3 min under magnetic stirring. The product was filtered, concentrated in vacuum and purified by column chromatography ($CH_2CI_2 \rightarrow 4\%$ MeOH/CH₂CI₂) to yield compound 15a (0.207 mmol, 0.133 g, 47% yield) as a yellow solid. Rf $(CH_2Cl_2/MeOH 10\%) = 0.53$. m.p = 87-89 °C. ¹H NMR (600 MHz, CDCl₃) δ 9.90 and 9.57 (2 br s, 1H), 7.42 and 7.11 (m, 12H), 5.82 and 5.66 (2 br s, 2H), 5.10 (s, 2H), 4.82 (br s, 1H), 4.66-4.59 (m, 2H), 4.10-3.84 (m, 8H), 3.71 (s, 3H), 2.08-2.00 (m, 4H), 1.06-0.94 (m, 6H). ¹³C NMR (150 MHz, CDCl₃) δ 171.0, 170.4, 170.3, 170.1, 168.5, 167.9, 156.7, 136.1, 134.7, 129.2, 128.9, 128.6, 128.3, 128.2, 126.8, 67.3, 64.4, 52.4, 51.8, 49.7, 43.5, 41.2, 41.0, 29.7, 27.1, 20.9, 19.6. HRMS (ESI) m/z: calcd. for $[M+Na]^+ C_{31}H_{40}N_6O_9Na$: 663.2754; found: 663.2755.

Compound 15b

To a solution of ester **11b** (1.96 mmol, 0.788 g) in THF/H₂O (2:1, 69 mL) was added LiOH (9.8 mmol, 0.235 g) at 0 °C. The reaction was stirred for 2.5 h at 0

°C, acidified with a 2 M solution of NaHSO₄ to pH 2 and extracted three times with ethyl acetate. The combined organic phases were dried with sodium sulfate and concentrated to yield the respective acid 13b (1.96 mmol, 0.761 g, quantitative yield), which was used without further purification. A sealed 10 mL glass tube containing a mixture of acid **13b** (1.63 mmol, 0.633 g), methanol (2.0 mL), benzylamine (3.25 mmol, 0.348 g), anhydrous sodium sulfate (0.975 g), paraformaldehyde (3.25 mmol, 0.0975 g) and methyl isocyanoacetate (9, 1.63 mmol, 0.15 mL) was introduced in the cavity of a microwave reactor (CEM Co., Discover) and irradiated at 80 °C for 3 min (ramp time: 100 s) under magnetic stirring. The residue was filtered, concentrated in vacuum and purified by column chromatography (CH₂Cl₂ \rightarrow 4% MeOH/CH₂Cl₂) to yield compound **15b** (1.23 mmol, 0.748 g, 76% yield) as a yellow solid. R_f (CH₂Cl₂/MeOH 15%) = 0.53. m.p = 79-81 °C. ¹H NMR (600 MHz, CDCl₃) δ 9.96 and 9.59 (2s, 1H), 7.37-7.22 (m, 5H), 4.84-4.76 (m, 1H), 4.71-4.60 (m, 2H), 4.25-3.78 (m, 8H), 3.74 (s, 3H), 2.16-1.95 (m, 4H), 1.43 (s, 9H), 1.11-1.02 (m, 2H), 0.95 (d, J = 6.2 Hz, 4H). ¹³C NMR (150 MHz, CDCl₃) δ 174.0, 170.9, 170.3, 168.9, 168.5, 168.0, 156.2, 134.8, 129.1, 128.8, 128.4, 128.0, 126.8, 80.4, 64.7, 52.4, 51.7, 49.5, 43.1, 41.2, 41.1, 28.2, 27.2, 20.9, 19.6. HRMS (ESI) m/z: calcd. for [M+Na]+ C₂₈H₄₂N₆O₉Na: 629.2911; found: 629.2905.

Compound 15c

To a solution of ester **11c** (0.803 mmol, 0.323 g) in THF/H₂O (2:1, 39 mL) was added LiOH (0.401 mmol, 0.096 g) at 0 °C. The reaction was stirred for 2 h at 0 °C, acidified with a 2 M solution of NaHSO₄ to pH 2 and extracted three times with ethyl acetate. The combined organic phases were dried with sodium sulfate

and concentrated to yield the respective acid **13c** (0.775 mmol, 0.301 g, 96% yield), which was used without further purification. To a solution of benzylamine (1.55 mmol, 0.166 g) in methanol (10 mL) were added sodium sulfate (0.20 g) and paraformaldehyde (1.55 mmol, 0.0465 g) and stirring was continued for 1 h at rt. Acid 13c (0.775 mmol, 0.301 g) was added and after 10 min methyl isocyanoacetate (0.775 mmol, 0.070 mL) was added. The reaction was stirred for 24 h at rt. After filtration, the solution was concentrated in vacuum and the residue was purified by column chromatography ($CH_2CI_2 \rightarrow 4\%$ MeOH/CH₂Cl₂) to yield compound 15c (0.425 mmol, 0.258 g, 55% yield) as a yellow solid. R_f $(CH_2CI_2/MeOH 10\%) = 0.44$. m.p = 84-86 °C. ¹H NMR (600 MHz, CDCI₃, presence of rotamers) δ 9.83 (br s, 1H), 8.58 (br s, 1H), 7.48 and 7.34 (2 br s, 1H), 7.28 and 7.10 (m, 6H), 5.87 and 5.78 (br s, 1H), 4.71-4.54 (m, 2H), 4.17-3.82 (m, 8H), 3.63 and 3.61 (2s, 3H), 2.33-2.26 and 2.16-2.09 (2m, 2H), 1.37-1.20 (m, 15H), 0.89-0.86 (m, 3H). ¹³C NMR (150 MHz, CDCl₃, presence of rotamers) δ 175.2, 172.0, 170.4, 170.1, 169.2, 168.6, 156.5, 135.3, 129.1, 128.7, 128.4, 128.0, 126.8, 80.6, 64.6, 52.3, 50.0, 49.4, 42.9, 41.8, 41.1, 28.3, 26.5, 24.4, 22.6, 8.4. HRMS (ESI) m/z: calcd. for $[M+Na]^+ C_{28}H_{42}N_6O_9Na$: 629.2911; found: 629.2903.

References

- Khan, K. M.; Rasheed, M.; Ullah, Z.; Hayat, S.; Kaukab, F.; Choudhary, M. I.; Rahman, A.-U.; Perveen, S. *Bioorg. Med. Chem.* **2003**, *11*, 1381-1387.
- Caplar, V.; Zinir, M.; Pozzo, J.-L.; Fages, F.; Mieden-Gundert, G.; Vogtle, F. *Eur. J. Org. Chem.* 2004, 4048-4059.
- 3. Ottersbach, P. A.; Schnakenburg, G.; Gütschow, M. *Chem. Commun.* **2012**, *48*, 5772-5774.
- Gaccioli, F.; Franchi-Gazzola, R.; Lanfranchi, M.; Marchio, L.; Metta, G.; Pellinghelli, M. A.; Tardito, S.; Tegoni, M. *J. Inorg. Biochem.* 2005, *99*, 1573-1584.

Spectra of compounds



Figure S1: ¹H NMR (300 MHz, CD₃OD) spectrum of compound 3a.



Figure S2: ¹³C NMR (75.46 MHz, CD₃OD) spectrum of compound 3a.



Figure S3: ¹H NMR (300 MHz, CD₃OD) spectrum of compound 3b.



Figure S4: ¹³C NMR (75.46 MHz, CD₃OD) spectrum of compound **3b**.



Figure S5: ¹H NMR (300 MHz, CD₃OD) spectrum of compound **3c**.



Figure S6: ¹³C NMR (75.46 MHz, CD₃OD) spectrum of compound 3c.



Figure S7: ¹H NMR (300 MHz, CDCI₃, presence of rotamers) spectrum of compound **11a**.



Figure S8: ¹³C NMR (75.46 MHz, CDCl₃, presence of rotamers) spectrum of compound **11a**.



Figure S9: ESI-HRMS of compound 11a.



Figure S10: ¹H NMR (300 MHz, CDCl₃, presence of rotamers) spectrum of compound 11b.



Figure S11: ¹³C NMR (75.46 MHz, DMSO-*d*₆, presence of rotamers) spectrum of compound **11b**.



Figure S12: ESI-HRMS of compound 11b.



Figure S13: ¹H NMR (600 MHz, CDCl₃, presence of rotamers) spectrum of compound 11c.



Figure S14: ¹³C NMR (150 MHz, CDCl₃, presence of rotamers) spectrum of compound **11c**.



Figure S15: ESI-HRMS of compound 11c.



Figure S16: ¹H NMR (600 MHz, CDCl₃, presence of rotamers) spectrum of compound 11d.



Figure S17: ¹³C NMR (150 MHz, CDCl₃, presence of rotamers) spectrum of compound 11d.



Figure S18: ESI-HRMS of compound 11d.



Figure S19: ¹H NMR (600 MHz, CDCl₃, presence of rotamers) spectrum of compound 11e.



Figure S20: ¹³C NMR (150 MHz, CDCl₃, presence of rotamers) spectrum of compound **11e**.



Figure S21: ESI-HRMS of compound 11e.



Figure S22: ¹H NMR (600 MHz, CDCI₃, presence of rotamers) spectrum of compound 11f.



Figure S23: ¹³C NMR (150 MHz, CDCl₃, presence of rotamers) spectrum of compound 11f.



Figure S24: ESI-HRMS of compound 11f.



Figure S25: ¹H NMR (600 MHz, CD₃OD) spectrum of compound **12a**.



Figure S26: ¹³C NMR (150 MHz, CD₃OD, presence of rotamers) spectrum of compound 12a.



Figure S27: ¹H NMR (600 MHz, CD₃OD) spectrum of compound **12b**.



Figure S28: ¹³C NMR (150 MHz, CD₃OD) spectrum of compound 12b.



Figure S29: ¹H NMR (600 MHz, CD₃OD) spectrum of compound 14a.



Figure S30: ¹³C NMR (150 MHz, DMSO- d_6) spectrum of compound 14a.



Figure S31: ESI-HRMS of compound 14a.



Figure S32: ¹H NMR (600 MHz, CDCl₃) spectrum of compound 14b.



Figure S33: 13 C NMR (150 MHz, CDCl₃) spectrum of compound 14b.



Figure S34: ESI-HRMS of compound 14b.



Figure S35: ¹H NMR (600 MHz, CDCl₃) spectrum of compound 15a.



Figure S36: ¹³C NMR (150 MHz, CDCl₃) spectrum of compound 15a.



Figure S37: ESI-HRMS of compound 15a.



Figure S38: ¹H NMR (600 MHz, CDCl₃) spectrum of compound 15b.



Figure S39: ¹³C NMR (150 MHz, DMSO-*d*₆) spectrum of compound **15b**.



Figure S40: ESI-HRMS of compound 15b.



Figure S41: ¹H NMR (600 MHz, CDCl₃, presence of rotamers) spectrum of compound 15c.



Figure S42: ¹³C NMR (150 MHz, CDCl₃, presence of rotamers) spectrum of compound **15c**.



Figure S43: ESI-HRMS of compound 15c.